Moleculin Biotech (MBRX) EBIT Growth (5y) (2021 - 2026)
Moleculin Biotech (MBRX) EBIT Growth (5y) (2021 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn |
| 10 | Moleculin Biotech | 3.35 Mn | 3.35 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -6.51% |
| Dec 31, 2025 | -16.60% |
| Sep 30, 2025 | 0.81% |
| Jun 30, 2025 | -2.59% |
| Mar 31, 2025 | -3.26% |
| Dec 31, 2024 | -6.66% |
| Sep 30, 2024 | -9.62% |
| Jun 30, 2024 | -11.23% |
| Mar 31, 2024 | -7.87% |
| Dec 31, 2023 | -15.51% |
| Sep 30, 2023 | -18.08% |
| Jun 30, 2023 | -3.27% |
| Mar 31, 2023 | -25.94% |
| Dec 31, 2022 | -15.74% |
| Sep 30, 2022 | -30.46% |
| Jun 30, 2022 | -41.30% |
| Mar 31, 2022 | -35.74% |
| Dec 31, 2021 | -29.72% |
| Sep 30, 2021 | -34.06% |
| Jun 30, 2021 | -50.10% |